BiosCompass AntiAD Adhesion Barrier Gel

Post-surgical adhesions can cause serious complications such as:

- Bowel obstruction, female infertility, and post-surgical pain. 

- The intestines and gall bladder may be damaged and other diseases may occur when a   

    second operation is performed. 

- Patients experiencing serious discomfort during their lifetime.

AntiAD is indicated to prevent or reduce post-operative adhesions, decrease post-surgical pain, promote healing and successful surgical outcomes.

The active component in AntiAD is an auto-crosslinked derivative of hyaluronic acid (HA), one of the main components of human connective tissue and of epithelial and mesothelial tissues. The auto-crosslinking process makes HA more viscous, and there is no other crosslinked molecule added during the process. Moreover, auto-crosslinked polysaccharides have increased viscosity and extended residence time, and auto-crosslinked polysaccharides also keep the same tolerability and biocompatibility with the original polymer.

AntiAD is totally synthetic auto-crosslinked hyaluronic acid, making it more biocompatible than hyaluran products derived from animals (chichens), and is less susceptible to adverse reaction by patients allergic to eggs and poultry.

General Instructions for Use

- After having brought the product into the operating theatre, open the blister package and transfer the syringe into the sterile field, adopting the normal aseptic techniques used in the surgical theaters.

- Remove the protective cap on the tip of the syringe and insert the provided cannula.

- Pushing the plunger, apply the gel inside surgical site.

- Cover the interested areas completely with the gel. Even if the thickness of the gel applied dose not influence the effacy of the product, it is recommended to apply a 1-2 mm thick layer of gel.

- Do not irrigate the surgical field, after application of the product.

To access the Instruction for Use (IFU) pdf document click the button labelled AntiAD IFU Datasheet.

Do not apply in patients with known sensitivity/allergy to AntiAD Gel or products containing sodium hyaluronate or who have anaphylactic shock history.

Do not use in patients with active infection or contamination of the surgical site.

Warnings and Precautions

- The safety and effacy of the product has been recognized internationally as suitable for reducing adhesion. According to the post-marketing surveillance data, so far there has been no serious adverse event or incident case reported.

- Even if, on the basis of preclinical evidences, the effacy of the product is not compromised in the presence of difficult haemostasis, the use of the product on patients affected by alterations of blood coagulation, severe allergies or with recognized previous anaphylaxis episodes, is at total discretion of the surgeon.

- The product is not a sealant.

- The concomitant use of the product together with other anti-adhesion devices or with solutions instilled intraperitoneally, has not been evaluated.

- AntiAD Adhesion Barrier Gel does not have intrinsic bacteriostatic or bactericidal activity.

- The safety of AntiAD Adhesion Barrier Gel has not been evaluated in patients affected by malignant tumors.

-Data on the use of AntiAD Adhesion Barrier Gel on pregnant women are not available and therefore the use of this device is not recommended in this condition. It is also recommended to avoid pregnancy during the first complete menstrual cycle subsequent to the treatment.

-AntiAD has not been clinically evaluated for use with a commercial dural or tissue sealant.

To access the Instruction for Use (IFU) pdf document click the button labelled AntiAD IFU Datasheet.